Circulating Omentin-1 levels and altered iron balance in chronic haemodialysis patients.
Omentin-1
TSAT
ferritin
haemodialysis
iron
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
22
06
2021
entrez:
2
3
2022
pubmed:
3
3
2022
medline:
3
3
2022
Statut:
epublish
Résumé
Iron deficiency is highly prevalent among patients undergoing chronic haemodialysis (HD) but its correct identification is often problematic as common biomarkers of iron status, such as transferrin saturation (TSAT) and ferritin, can be altered by inflammation or malnutrition. In this pilot multicentre study, we aimed at evaluating circulating levels of Omentin-1, a novel fat depot-specific adipokine that is also involved in iron regulation, in a cohort of 85 chronic HD patients with relation to their iron status. Omentin-1 levels in HD were statistically higher than in healthy controls (P = 0.03) and there was a significant, growing trend in all iron parameters across Omentin-1 tertiles (P < 0.001). Compared with patients with optimal iron status, Omentin-1 levels were lower in subjects categorized according to TSAT ≤20% or serum ferritin ≤200 μg/L (both P < 0.001) and even more reduced in 19 patients (22%) simultaneously displaying low levels of both markers (P < 0.001). In this latter group, Omentin-1 levels increased in parallel to all other iron markers after iron correction by i.v. supplementation. At multivariate regression analyses, ferritin (β = 0.71; P < 0.001) and TSAT (β = 0.32; P = 0.03) remained the sole independent predictors of Omentin-1 levels. This biomarker also showed a remarkable diagnostic capacity at receiver operating characteristic analyses in identifying iron-depleted HD patients according to a criterion of TSAT ≤20% [area under the curve (AUC) 0.827], ferritin ≤200 μg/L (AUC 0.863) or low levels of both parameters (AUC 0.907). Findings obtained indicate that Omentin-1 is somewhat involved in iron balance regulation and might be a candidate biomarker for diagnosing and managing altered iron conditions in HD patients.
Sections du résumé
BACKGROUND
BACKGROUND
Iron deficiency is highly prevalent among patients undergoing chronic haemodialysis (HD) but its correct identification is often problematic as common biomarkers of iron status, such as transferrin saturation (TSAT) and ferritin, can be altered by inflammation or malnutrition.
METHODS
METHODS
In this pilot multicentre study, we aimed at evaluating circulating levels of Omentin-1, a novel fat depot-specific adipokine that is also involved in iron regulation, in a cohort of 85 chronic HD patients with relation to their iron status.
RESULTS
RESULTS
Omentin-1 levels in HD were statistically higher than in healthy controls (P = 0.03) and there was a significant, growing trend in all iron parameters across Omentin-1 tertiles (P < 0.001). Compared with patients with optimal iron status, Omentin-1 levels were lower in subjects categorized according to TSAT ≤20% or serum ferritin ≤200 μg/L (both P < 0.001) and even more reduced in 19 patients (22%) simultaneously displaying low levels of both markers (P < 0.001). In this latter group, Omentin-1 levels increased in parallel to all other iron markers after iron correction by i.v. supplementation. At multivariate regression analyses, ferritin (β = 0.71; P < 0.001) and TSAT (β = 0.32; P = 0.03) remained the sole independent predictors of Omentin-1 levels. This biomarker also showed a remarkable diagnostic capacity at receiver operating characteristic analyses in identifying iron-depleted HD patients according to a criterion of TSAT ≤20% [area under the curve (AUC) 0.827], ferritin ≤200 μg/L (AUC 0.863) or low levels of both parameters (AUC 0.907).
CONCLUSIONS
CONCLUSIONS
Findings obtained indicate that Omentin-1 is somewhat involved in iron balance regulation and might be a candidate biomarker for diagnosing and managing altered iron conditions in HD patients.
Identifiants
pubmed: 35233284
doi: 10.1093/ckj/sfab189
pii: sfab189
pmc: PMC8874876
doi:
Types de publication
Journal Article
Langues
eng
Pagination
303-310Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.
Références
J Am Soc Nephrol. 2020 Mar;31(3):456-468
pubmed: 32041774
Bone Res. 2018 Mar 30;6:9
pubmed: 29619269
Nutrients. 2017 Jul 28;9(8):
pubmed: 28788066
Nephrol Dial Transplant. 2004 Jan;19(1):141-9
pubmed: 14671049
J Hum Hypertens. 2021 Mar;35(3):290-295
pubmed: 32978495
Compr Physiol. 2017 Jun 18;7(3):765-781
pubmed: 28640441
PLoS One. 2019 Dec 10;14(12):e0226292
pubmed: 31821362
Curr Vasc Pharmacol. 2014 Jan;12(1):136-43
pubmed: 22724476
Diabetes Res Clin Pract. 2015 Oct;110(1):44-50
pubmed: 26293449
Scand J Immunol. 2020 Jul;92(1):e12882
pubmed: 32243627
Nephrol Dial Transplant. 1999 Mar;14(3):659-65
pubmed: 10193816
Acta Haematol. 2019;142(1):44-50
pubmed: 30970355
Cardiovasc Diabetol. 2011 Nov 22;10:103
pubmed: 22108456
Hemodial Int. 2017 Jun;21 Suppl 1:S78-S82
pubmed: 28403561
Nephrol Dial Transplant. 2009 Nov;24(11):3398-403
pubmed: 19549696
Am J Hematol. 2017 Oct;92(10):1068-1078
pubmed: 28612425
Semin Nephrol. 2016 Mar;36(2):87-93
pubmed: 27236128
Int Urol Nephrol. 2021 May;53(5):935-944
pubmed: 33025407
Nephrol Dial Transplant. 2013 Jun;28(6):1346-59
pubmed: 23585588
J Pediatr. 2016 Jun;173 Suppl:S16-28
pubmed: 27234407
Clin J Am Soc Nephrol. 2008 Nov;3(6):1691-701
pubmed: 18922994
Nutrients. 2018 Aug 27;10(9):
pubmed: 30150549
Kidney Blood Press Res. 2012;35(6):511-6
pubmed: 22813935
Int Urol Nephrol. 2016 Jul;48(7):1145-54
pubmed: 27023478
Ir J Med Sci. 2021 Feb;190(1):97-106
pubmed: 32583310
Am J Kidney Dis. 2004 Apr;43(4):671-84
pubmed: 15042544
J Biochem. 2013 Nov;154(5):437-48
pubmed: 23921499